orantinib has been researched along with Liver Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, Y; Arioka, H; Cheng, AL; Chiu, CF; Heo, J; Hidaka, H; Izumi, N; Kudo, M; Lee, YJ; Liang, PC; Morita, S; Park, JH; Park, JW; Sheen, IS | 1 |
| Arai, Y; Aramaki, T; Arioka, H; Furuse, J; Hidaka, H; Ikeda, M; Imanaka, K; Inaba, Y; Izumi, N; Kanazawa, S; Kaneko, S; Kora, S; Kudo, M; Matsui, O; Morita, S; Okusaka, T; Saito, H; Yamashita, T; Yokosuka, O | 1 |
| Arai, Y; Aramaki, T; Arioka, H; Imanaka, K; Inaba, Y; Kanai, F; Kaneko, S; Kawai, N; Kora, S; Kudo, M; Matsui, O; Nishida, N; Seki, H; Tanaka, T; Yamakado, K; Yamamoto, T | 1 |
| Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H | 1 |
| Asahina, Y; Hara, Y; Hashiba, T; Hayashi, T; Honda, M; Kaneko, S; Kondo, M; Nio, K; Nomura, Y; Oishi, N; Okada, H; Sunagozaka, H; Yamashita, T; Yoshida, M | 1 |
| Arioka, H; Ikeda, M; Kanai, F; Kawabe, T; Kondo, Y; Morizane, C; Obi, S; Okusaka, T; Omata, M; Sato, S; Shiina, S; Tagawa, K; Taniguchi, M; Tateishi, R; Yoshida, H | 1 |
| Enooku, K; Goto, T; Kanai, F; Koike, K; Kondo, Y; Masuzaki, R; Omata, M; Shiina, S; Tateishi, R; Yoshida, H | 1 |
| Chikahisa, LM; Hasegawa, H; Kitajima, M; Kubota, T; Ozawa, S; Watanabe, M; Yamada, Y; Yorozuya, K | 1 |
| Jiang, XT; Tao, HQ; Zou, SC | 1 |
| Bucana, CD; Ellis, LM; Gallick, GE; Jung, YD; McConkey, DJ; McMahon, G; Solorzano, CC | 1 |
5 trial(s) available for orantinib and Liver Neoplasms
| Article | Year |
|---|---|
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Survival Analysis; Treatment Outcome | 2018 |
A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxindoles; Propionates; Proportional Hazards Models; Pyrroles; Time Factors; Treatment Outcome | 2013 |
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Tegafur; Treatment Outcome | 2014 |
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Area Under Curve; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Necrosis; Oxindoles; Propionates; Pyrroles; Survival Analysis; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2011 |
Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Precursors; Prothrombin; Pyrroles; Time Factors; Treatment Outcome; Tumor Burden | 2012 |
5 other study(ies) available for orantinib and Liver Neoplasms
| Article | Year |
|---|---|
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Humans; Indoles; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Survival Rate; Treatment Outcome | 2019 |
TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Mice; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Transforming Growth Factor beta1 | 2015 |
TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; HT29 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Pyrroles; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Stomach Neoplasms | 2006 |
In vivo intracellular signaling as a marker of antiangiogenic activity.
Topics: Androstadienes; Angiogenesis Inhibitors; Biomarkers, Tumor; Blotting, Western; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Fluorescent Antibody Technique; Humans; Indoles; Liver Neoplasms; Lymphokines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wortmannin | 2001 |